John Osborne
Cardiovascular Disease · Grapevine, TXNPI 1114929718
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $931,977 of the $1,328,823 with a category attached, or 70.1%. It is spread thinly across 34 manufacturers, the largest accounting for just 23.4%. Among cardiovascular disease clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,109 payments — averaging $1198.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$311K
- Amarin Pharma, Inc.$283K
- Boehringer Ingelheim$218K
- Novartis$187K
- Lilly USA, LLC$139K
- Sanofi-aventis U.S. LLC$73K
- plus $118K from 28 others
Across 13 payments — averaging $2191.54 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- PTC Therapeutics, Inc.$25K
- Cleerly, Inc.$3K
- Novartis$1K
What the payments were for
- Consulting fees$180,02214%
- Speaking & faculty fees$931,97770%
- Travel & lodging$151,40411%
- Food & beverage$21,9302%
- Education$1240%
- Other$43,3653%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 187 | $311,282 |
| Amarin Pharma, Inc. | 292 | $283,073 |
| Boehringer Ingelheim | 185 | $218,159 |
| Novartis | 38 | $186,947 |
| Lilly USA, LLC | 146 | $138,791 |
| Sanofi-aventis U.S. LLC | 77 | $72,817 |
| Esperion Therapeutics, Inc. | 68 | $67,794 |
| Cleerly, Inc. | 12 | $13,570 |
| United Imaging Healthcare North America, Inc. | 6 | $11,814 |
| E.r. Squibb & Sons, L.L.C. | 14 | $9,128 |
| Genentech, Inc. | 3 | $7,293 |
| Regeneron Healthcare Solutions, Inc. | 7 | $1,831 |
| AstraZeneca | 8 | $1,352 |
| Siemens Medical Solutions USA, Inc. | 5 | $851 |
| United Imaging Healthcare North America LLC | 4 | $464 |
| Canon Medical Systems USA, Inc. | 1 | $415 |
| Merck | 16 | $381 |
| Itamar Medical Inc | 3 | $335 |
| Regeneron | 5 | $318 |
| Amgen | 3 | $288 |
| Heartflow, Inc. | 4 | $272 |
| Agepha Pharma FZ LLC | 1 | $257 |
| Lexicon Pharmaceuticals, Inc. | 2 | $236 |
| Pfizer | 2 | $230 |
| Johnson & Johnson | 3 | $203 |
| GE HealthCare | 3 | $154 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $130 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $120 |
| Bayer | 2 | $76 |
| Corcept Therapeutics | 1 | $75 |
| Arbor Pharmaceuticals, Inc. | 3 | $73 |
| Alnylam Pharmaceuticals Inc. | 3 | $63 |
| Trevena, Inc. | 1 | $19 |
| Genentech USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,328,823 in reported general payments places this provider in the 95th percentile of 1,515 cardiovascular disease providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 47 | $63,762 |
| OzempicSemaglutide | 41 | $48,492 |
| MounjaroTirzepatide | 37 | $40,877 |
| JardianceEmpagliflozin | 56 | $39,184 |
| EntrestoSacubitril/Valsartan | 22 | $22,755 |
| NexlizetBempedoic Acid/Ezetimibe | 23 | $21,240 |
| VascepaIcosapent Ethyl | 19 | $14,089 |
| Repatha SureclickEvolocumab | 17 | $13,445 |
| Icosapent Ethyl | 23 | $5,339 |
| Flecainide Acetate | 12 | $1,776 |
| Eplerenone | 12 | $1,496 |
| Rosuvastatin Calcium | 73 | $784 |
| Olmesartan Medoxomil | 32 | $504 |
| Ezetimibe | 25 | $381 |
| Zolpidem Tartrate | 17 | $317 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $230 | $63,76247 claims |
| Novo NordiskOzempic | $311,282 | $48,49241 claims |
| Lilly USA, LLCMounjaro | $138,791 | $40,87737 claims |
| Boehringer IngelheimJardiance | $218,159 | $39,18456 claims |
| NovartisEntresto | $186,947 | $22,75522 claims |
| Esperion Therapeutics, Inc.Nexlizet | $67,794 | $21,24023 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in Grapevine
- Vikas JainGrapevine$261K
- Paul BhellaGrapevine$194K
- Ramin Farzaneh-FarDallas$17.1M
- Darren McGuireDallas$1.2M
- Peter McCulloughDallas$664K
- Ann NavarDallas$616K
- Biykem BozkurtHouston$606K
- Milton PackerDallas$530K
- Amarinder BindraDallas$512K
- Robert SalazarKingwood$478K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.